Rising ETF's - 401K option
With the drop from profit taking in medical cannabis / HEMP CBD ETF's just looking to compare MJ, TOKE and THCX as some of top ETF's in this sector.
Did you know you can trade ETF's in 401K fund? Ask your investment holder about this option, as ETF/ETP's are like Mutual Funds, but offer typically lower fee's and entry/exit like a stock.
* With recent pullback all nearing golden ratio retracement 0.618.
* All 3 have shown similar RSI
* THCX was most up on close 2.12 over MJ, TOKE
* Legalization expanding, medical benefits of CBD as well and now we're past initial market cycle of segment IPO's and into longer term profit cycle and secondary market investing.
* Profitability for most still on-going issue for as they weather early start-up issues (mite/disease/energy/waste/cash flow vs multi-state/country operations growth)
* Await Genomic (CRSPR Cas9) improvements in next 1-2 years with improved resistance to spider mite attack with optimized benefits without crop loss risks of past half-decade by all the large growers.
* Nicotine reduced crops (Twenty Second Century Growth IP) NYSE:XXII
XXII
Did you know you can trade ETF's in 401K fund? Ask your investment holder about this option, as ETF/ETP's are like Mutual Funds, but offer typically lower fee's and entry/exit like a stock.
* With recent pullback all nearing golden ratio retracement 0.618.
* All 3 have shown similar RSI
* THCX was most up on close 2.12 over MJ, TOKE
* Legalization expanding, medical benefits of CBD as well and now we're past initial market cycle of segment IPO's and into longer term profit cycle and secondary market investing.
* Profitability for most still on-going issue for as they weather early start-up issues (mite/disease/energy/waste/cash flow vs multi-state/country operations growth)
* Await Genomic (CRSPR Cas9) improvements in next 1-2 years with improved resistance to spider mite attack with optimized benefits without crop loss risks of past half-decade by all the large growers.
* Nicotine reduced crops (Twenty Second Century Growth IP) NYSE:XXII
XXII
면책사항
해당 정보와 게시물은 금융, 투자, 트레이딩 또는 기타 유형의 조언이나 권장 사항으로 간주되지 않으며, 트레이딩뷰에서 제공하거나 보증하는 것이 아닙니다. 자세한 내용은 이용 약관을 참조하세요.
면책사항
해당 정보와 게시물은 금융, 투자, 트레이딩 또는 기타 유형의 조언이나 권장 사항으로 간주되지 않으며, 트레이딩뷰에서 제공하거나 보증하는 것이 아닙니다. 자세한 내용은 이용 약관을 참조하세요.